1Phipps RIR Atherosclerosis: the emerging role of inflammmation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000: 97: 6930-2.
2Michelson AD. Barnard MR. Krueger LA. Frelinger AL 3rd.Furman MI. Evaluation of platelet function by flow cytometry. Methods 2000: 21: 259-70.
3Kaski JC. Chester MR. Chen L. Katritsis D. Rapid anglographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis norphology .Circulation 1995: 92: 2058-65.
4Kai H. lkeda H. Yasukawa H. Kai M. Seki Y. Kuwahara F. et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary s vndronles. J Am Coil Cardiol 1998: 32: 368-72.
5Inokubo Y.Hanada H. Ishizaka H. Fukushi T. Kamada T.Okumura K.Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-7.
6Yan JC. Wu ZG. Li L. Zhong RQ. Kong XT. The clinical implications of increased expression of CD40L in patients with acute coronary syndromes, Chin Med J 2002: 115:491-3.
7Peng DQ. Zhao SP. Li YF. Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002: 319: 19-26.
8Phipps RP. Koumas L. Leung E. Reddy SY. Blieden T.Kaufman J. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis. Curt Opin lnvestig Drugs 2001: 2: 773-7.
9Ozmen J. Bobryshev YV, Lord RS. CD40 co-stimulatory molecule expression by dendritic cells in primary atherosclerotic lesions in carotid arteries and in stenotic saphenous vein coronary artery grafts. Cardiovasc Surg 2001: 9: 329-33.
10Math F. Schonbeck U. Sukhova GK. Atkinson E. Libby P.Reduction of atherosclerosis in mice by inhibition CD40 sinalling. Nature 1998: 394: 200-3.
